EPICS Congress Coverage: ASCO GU 2022 Highlights

Expert perspectives and strategic insights on the latest therapeutic developments in GU malignancies

February 22, 2022
Daniel Petrylak, MD, Yale, Aptitude Health


Daniel Petrylak, MD

Yale Cancer Center, New Haven, CT, US

Faculty Members

Ulka Vaishampayan, MBBS
Rogel Cancer Center, Ann Arbor, MI, US

Leonard Gomella, MD, FACS
Sidney Kimmel Cancer Center, Philadelphia, PA, US

Robert Dreicer, MD, MACP, FASCO
University of Virginia Cancer Center, Charlottesville, VA, US

Oliver Sartor, MD
Tulane Cancer Center, New Orleans, LA, US

Scott Tagawa, MD, FACP
Weill Cornell Medicine, New York, NY, US

David Nanus, MD
Weill Cornell Medicine, New York, NY, US

Karim Fizazi, MD, PhD
Gustave Roussy, Villejuif, France

Sample Report

Start discovering the insights

View Report


The generated report based on the meeting includes the following topics

  • Prostate Cancer Part 1 – Hormonal Therapies and Chemotherapies
  • Prostate Cancer Part 2 – Targeted Therapies
  • Bladder Cancer Part 1 – ADCs
  • Bladder Cancer Part 2 – PARP Inhibitors and Immunotherapies
  • Renal Cell Carcinoma

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.